Wilmington Savings Fund Society FSB lessened its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 4.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 290,871 shares of the biopharmaceutical company's stock after selling 14,800 shares during the quarter. Wilmington Savings Fund Society FSB's holdings in Pfizer were worth $7,051,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also recently bought and sold shares of the company. GKV Capital Management Co. Inc. bought a new position in Pfizer in the 1st quarter valued at $27,000. Bayforest Capital Ltd bought a new position in Pfizer in the 1st quarter valued at $28,000. North Capital Inc. bought a new position in Pfizer in the 1st quarter valued at $28,000. WPG Advisers LLC purchased a new position in shares of Pfizer during the 1st quarter valued at $35,000. Finally, Horizon Financial Services LLC purchased a new position in shares of Pfizer during the 1st quarter valued at $35,000. Institutional investors own 68.36% of the company's stock.
Analyst Ratings Changes
A number of research analysts have recently commented on the company. Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Wall Street Zen cut Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday, September 28th. Morgan Stanley dropped their price target on Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a research report on Friday. UBS Group reaffirmed a "neutral" rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $28.35.
Read Our Latest Stock Report on Pfizer
Pfizer Stock Performance
Shares of PFE opened at $24.53 on Wednesday. The stock's 50-day simple moving average is $24.88 and its 200 day simple moving average is $24.12. The stock has a market capitalization of $139.44 billion, a price-to-earnings ratio of 13.05, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.82.
Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Pfizer Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer's dividend payout ratio is currently 91.49%.
Pfizer Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
